Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 2, 2010, Pages 172-177

  Ouellet, Georges ^a   Cardinal, Héloïse ^a   Mailhot, Marjolaine ^a   Ste Marie, Louis Georges ^a   Roy, Louise ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Calcium carbonate; Chelating agents; Hemodialysis; Phosphate; Sevelamer

Indexed keywords

ALBUMIN; BICARBONATE; CALCIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; BINDING AFFINITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REGIMEN; DRUG PREFERENCE; EATING HABIT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CALCIUM CARBONATE; CHELATING AGENTS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 77950209228     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00748.x     Document Type: Article

References (19)

1. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease undergoing dialysis. N Engl J Med 2000 342 : 1478 1483.
2. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002 62 : 245 252.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15 : 2208 2218.
4. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005 46 : 925 932.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 : S1 S201.
6. Zimmerer JL, Leon JB, Covinsky KE, Desai U, Sehgal AR. Diet monotony as a correlate of poor nutritional intake among hemodialysis patients. J Ren Nutr 2003 13 : 72 7.
7. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004 65 : 1914 1926.
8. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2003 17 : 1642 1648.
9. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium. Clin Nephrol 1999 51 : 18 26.
10. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin Nephrol 1998 50 : 381 386.
11. Rutishauser I. Dietary intake measurements. Public Health Nutr 2005 8 : 1100 1107.
12. Gersovitz M, Madden JP, Smiciklas-Wright H. Validity of the 24-hr. Dietary recall and seven-day record for group comparisons. J Am Diet Assoc 1978 73 : 48 55.
13. Braulin W, Zhorov E, Guo A et al. Bile acid binding to sevelamer HCl. Kidney Int 2002 62 : 611 619.
14. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999 14 : 2907 2914.
15. Plone MA, Petersen JS, Rosenbaum DP, Burke SK. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002 41 : 517 523.
16. Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. Am J Kidney Dis 2006 48 : 437 444.
17. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 2004 Supplement 90 : S39 45.
18. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of non-adherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008 9 : 2.
19. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002, Issue 2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.